RBC Capital analyst Brian Abrahams maintained a Buy rating on IGM Biosciences (NASDAQ:IGMS) Inc on Thursday, setting a price target of $107, which is approximately 20.09% above the present share price of $89.1.
Abrahams expects IGM Biosciences Inc to post earnings per share (EPS) of -$0.95 for the second quarter of 2021.
The current consensus among 4 TipRanks analysts is for a Strong Buy rating of shares in IGM Biosciences, with an average price target of $110.5.
The analysts price targets range from a high of $119 to a low of $102.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $0 and a net profit of -$31.71 million. The company's market cap is $2.85 billion.
According to TipRanks.com, RBC Capital analyst Brian Abrahams is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 6.9% and a 48.20% success rate.
IGM Biosciences, Inc. operates as a biotechnology company which develops antibodies for the treatment of cancer. It offers IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The company was founded in 2010 and is headquartered in Mountain View, CA.